Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function

Circulation Research

Volumn 85, Issue 4, 1999, Pages 364-376

  Spinale, Francis G ^a,c   Coker, Mytsi L ^a   Krombach, Stephen R ^a   Mukherjee, Rupak ^a   Hallak, Hussein ^b   Houck, Ward V ^a   Clair, Mark J ^a   Kribbs, Scott B ^a   Johnson, Linda L ^b   Peterson, J Thomas ^b   Zile, Michael R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b PFIZER INC   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Congestive heart failure; Metalloproteinases; Myocyte function

Indexed keywords

MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR;

ARTICLE; COLLAGEN DEGRADATION; CONGESTIVE HEART FAILURE; DISEASE COURSE; ENZYME ACTIVITY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINASE INHIBITION;

EID: 0033588199     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.85.4.364     Document Type: Article

References (63)

1. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahan S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, for the SOLVD investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction. Circulation. 1993;88:2277-2283.
2. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R, for the V-HeFT VA Cooperative Studies Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation. 1993;87(suppl VI): VI5-VI16.
3. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314;1547-1552.
4. Baughman K. New medical therapies for advanced left ventricular dysfunction. Cardiol Clin. 1995;13:27-34.
5. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 1998;82:482-495.
6. Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale FG. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol. 1998;274: H1506-H1523.
7. Bozkurt B, Kribbs SB, Clubb FJ, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann D. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97: 1382-1391.
8. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH. Angiotensin converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 1994;90:1410-1422.
9. Litwin SE, Katz SE, Weinburg EO, Lorell BH, Aurigemma GP, Douglas PS. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy: chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation. 1995;91;2642-2654.
10. Factor SM. Role of extracellular matrix in dilated cardiomyopathy. Heart Failure. 1994;9:260-268.
11. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC, Cruickshank JM, Devereux RB, Giles TD, Corsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvany MJ, Strauer BE. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992; 20:3-16.
12. Borg TK, Burgess ML. Holding it all together: organization and function(s) of the extracellular matrix of the heart. Heart Failure. 1993;8: 230-238.
13. Borg TK, Terracio L. Interaction of the extracellular matrix with cardiac myocytes during development and disease. In: Robinson TF, Kinne RKH, eds. Cardiac Myocyte-Connective Tissue Interactions in Health and Disease. Basel, Switzerland: Karger; 1990:113-130.
14. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991;261: H308-H318.
15. Komamura K, Shannon RP, Ihara T, Shen YT, Mirsky I, Bishop SP, Vatner SF. Exhaustion of the Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol. 1993;265:H1119-H1131.
16. Weber KT, Pick R, Silver MA, Moe GW, Janicki JS, Zucker IH, Armstrong PW. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation. 1990;82:1387-1401.
17. Weber KT, Janicki JS, Shroff S. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res. 1988;62:757-765.
18. Woessner FJ. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
19. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol. 1996;148: 1345-1350.
20. Lee E, Vaughan DE, Parikh SH, Grodzinsky AJ, Libby P, Lark MW, Lee RT. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ Res. 1996;78:44-49.
21. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151-160.
22. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P. Cytokine stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-189.
23. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia, PA: WB Saunders Co Inc; 1993:248-268.
24. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
25. Janicki JS, Henegar JR, Campbell SE, Tyagi SC. Myocardial collagenase activity in experimental dilated cardiomyopathy. In: Weber KT, ed. Wound Healing Responses in Cardiovascular Diseases. New York, NY: Futura Press; 1995:73-81.
26. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97:1708-1715.
27. Gunja-Smith A, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Am J Pathol. 1996;148:1639-1648.
28. Spinale FG, Fulbright BM, Mukherjee R, Tanaka R, Hu J, Crawford FA, Zile MR. Relationship between ventricular and myocyte function with tachycardia induced cardiomyopathy. Circ Res. 1992;71:174-187.
29. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim AE, Powell JR, Koster WH. Angiotensin converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation. 1995;92; 562-568.
30. Ye QZ, Johnson LL, Hupe DJ, Baragi V. Purification and characterization of the human stromelysin catalytic domain expressed in Escherichia coli. Biochemistry. 1992;31:11231-11235.
31. Ye QZ, Johnson LL, Nordan I, Hupe D, Hupe L. A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors. J Med Chem. 1994;37:206-209.
32. Ye QZ, Johnson LL, Yu AE, Hupe D. Reconstructed 19 kDa domain of gelatinase A is an active proteinase. Biochemistry. 1995;34:4702-4708.
33. Bunning P, Homquist B, Riordan JF. Substrate specificity and kinetic characteristics of angiotensin converting enzyme. Biochemistry. 1983;22: 103-110.
34. Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D'Adamio L, Hersh LB, Reinherz EL. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 (enkephalinase): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A. 1989;86:297-301.
35. Ahn K, Sisneros A, Herman SB, Pan SM, Hupe D, Lee C, Nikam S, Cheng XM, Doherty AM, Schroeder RL, Haleen SJ, Kaw S, Emoto N, Yanagisawa M. Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun. 1995;243: 184-190.
36. Welker P, Lippert U, Nurnberg W, Kruger-Krasagakes S, Moller A, Czarnetzki B. Glucocorticoid induced modulation of cytokine secretion from normal and leukemic human myelomonocytic cells. Int Arch Allergy Immunol. 1996;109:110-115.
37. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, Kirlin P, Greenberg B, Quinones MA, Yusuf S for the SOLVD investigators. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. J Am Coll Cardiol. 1993;22:146A-153A.
38. Swedberg K, Eneroth P, Kjekshus J, Willhelmsen L, for the CONCENSUS trial study group: hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
39. Zellner JL, Spinale FG, Eble DM, Hewett KW, Crawford FA. Alterations in myocyte shape and basement membrane attachment with tachycardia induced heart failure. Circ Res. 1991;69:590-600.
40. Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass, and function during development and regression of supraventricular tachycardia-induced cardiomyopathy: disparity between recovery of systolic vs diastolic function. Circulation. 1991;83:635-644.
41. Spinale FG, Tempel GE, Mukherjee R, Eble DM, Brown R, Vacchiano C, Zile MR. Cellular and molecular changes in the β-adrenergic receptor system with supraventricular tachycardia induced cardiomyopathy. Cardiovasc Res. 1994;28:1243-1250.
42. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS. Stress-shortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation. 1989;79:872-883.
43. Shimizu G, Zile MR, Blaustein AS, Gaasch WH. Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements. Circulation. 1985;71:266-272.
44. Colan SD, Borrow KM, Neuman A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load independent index of myocardial contractility. J Am Coll Cardiol. 1984;4:715-724.
45. Gaasch WH, Freeman GL. Functional properties of normal and failing hearts. In: McCall D, Rahimtoola SH, eds. Heart Failure. New York, NY: Chapman and Hall; 1995:14-29.
46. Morgan DE, Tomlinson CW, Qayumi AK, Toleikis PM, McConville B, Jamieson WRE. Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing. J Am Coll Cardiol. 1989;14:489-495.
47. Janicki JS, Matsubara BB. Myocardial collagen and left ventricular diastolic dysfunction. In: Gaasch WH, LeWinter MM, eds. Left Ventricular Diastolic Dysfunction and Heart Failure. Philadelphia, Pa: Lea and Febiger; 1994:125-140.
48. Kato S, Spinale FG, Tanaka R, Johnson W, Cooper G, Zile MR. Inhibition of collagen cross-linking: effects on fibrillar collagen and left ventricular diastolic function. Am J Physiol. 1995;269:H863-H868.
49. Solomon SB, Nikolic SD, Glantz SA, Yellin EL. Left ventricular diastolic function of remodeled myocardium in dogs with pacing-induced heart failure. Am J Physiol. 1998;274:H945-H954.
50. Wolff MR, de Tombe PP, Yasuhiko H, Burkhoff D, Bier S, Hunter WC, Gertstenblith G, Kass DA. Alterations in left ventricular mechanics, energetics, and contractile reserve in experimental heart failure. Circ Res. 1992;70:516-529.
51. Komamura K, Shannon RP, Pasipoularides A, Ihara T, Lader AS, Patrick TA, Bishop SP, Vatner SF. Alterations in left ventricular diastolic function in conscious dogs with pacing induced heart failure. J Clin Invest. 1992;89:1825-1838.
52. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picosirius red staining and circularly polarized light. Basic Res Cardiol. 1994;89:397-410.
53. Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H. Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukemia and HT1080 fibrosarcoma cells. Biochem J. 1992;285:603-611.
54. Barletta J, Angella G, Balch K, Dimova H, Stern G, Moser M, Selten G, Schultz G. Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor. Invest Ophthalmol Vis Sci. 1996;37:20-28.
55. Grobelny D, Poncz L, Galardy R. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992;31:7152-7154.
56. Robinson TF, Cohen-Gould L, Factor SM. Skeletal framework of mammalian heart muscle: arrangement of inter- and pericellular connective tissue structures. Lab Invest. 1983;49:482-498.
57. Spinale FG. The extracellular matrix with the development and regression from dilated cardiomyopathy. In: Weber KT, ed. Wound Healing Responses in Cardiovascular Diseases. Armonk, NY: Futura Press, Inc; 1995:83-98.
58. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol. 1992;54: 227-241.
59. Takahashi S, Barry AC, Factor SM. Collagen degradation in ischemic rat hearts. Biochem J. 1990;265:233-241.
60. Eble DM, Walker JD, Mukherjee R, Samarel AM, Spinale FG. Myosin heavy chain synthesis is increased in a rabbit model of heart failure. Am J Physiol 1997;272:H969-H978.
61. Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W, Olivetti G, Hintze TH, Anversa P. The cellular basis of pacing induced cardiomyopathy: myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation. 1995;92;2306-2317.
62. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry. 1990;29; 5783-5789.
63. Perreault CL, Shannon RP, Komamura K, Vatner SF, Morgan JP. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing induced heart failure. J Clin Invest. 1992;89:932-938.